NeoGenomics, Inc. (NEO) — 分析摘要
NeoGenomics, Inc.（NEO）的市值为2.39十亿美元，最近一年的营收同比增长了+10.1%。净利润率为-14.9%。当前市盈率为-24.1倍。
核心要点
- 营收同比变化+10.1%
- 净利润率-14.9%
- 市盈率-24.1倍
与SERVICES-TESTING LABORATORIES板块的其他公司相比，NEO的营收增长为+10.1%，市盈率为-24.1倍。
NeoGenomics, Inc. (NEO)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -38.9x — 盈利不足以覆盖利息支出
营业利润率为 -14.2% — 经营亏损显著
最新报表显示自由现金流为负。
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
行业
SERVICES-TESTING LABORATORIES
员工人数
2,500
总部
FORT MYERS, FL
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。